Latest News - Alimera Sciences

Monday, November 23, 2015 | Clinical Trials, Alimera Sciences

Alimera Sciences Announces New 36-Month Analysis That Shows Iluvien Slows Diabetic Retinopathy Progression

Alimera Sciences announced that a new analysis of patients from the FAME Study demonstrated a significant slowing of the progression of diabetic retinopathy (DR) in patients with diabetic macular edem…

Read the full story

Monday, November 16, 2015 | Clinical Trials, Retina, Alimera Sciences

Alimera Sciences Announces New 36-Month Analysis That Shows Iluvien Slows Diabetic Retinopathy Progression

Alimera Sciences announced that a new analysis of patients from the FAME Study demonstrated a significant slowing of the progression of diabetic retinopathy (DR) in patients with diabetic macular edem…

Read the full story

Tuesday, September 29, 2015 | Clinical Trials, Retina, Alimera Sciences

Alimera Sciences Limited Announces Availability Of Review Paper On Real World Experience With Iluvien

Alimera Sciences Limited, the European subsidiary of Alimera Sciences, announced the availability of real world data from 28 injections of Iluvien (fluocinolone acetonide 190 micrograms intravitreal i…

Read the full story

Tuesday, July 21, 2015 | Partnerships, Alimera Sciences

Alimera Sciences Signs Knight Therapeutics as Exclusive Iluvien Distributor for Canada

Alimera Sciences announced that it has signed an exclusive agreement with Knight Therapeutics, a Canadian specialty pharmaceutical company, for the distribution in Canada of Iluvien, Alimera’s s…

Read the full story